The estimated Net Worth of Paul Angelico is at least $31.9 ezer dollars as of 28 October 2022. Mr Angelico owns over 47,812 units of Chembio Diagnostics stock worth over $31,875 and over the last 2 years he sold CEMI stock worth over $0.
Mr has made over 1 trades of the Chembio Diagnostics stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 47,812 units of CEMI stock worth $21,994 on 28 October 2022.
The largest trade he's ever made was exercising 47,812 units of Chembio Diagnostics stock on 28 October 2022 worth over $21,994. On average, Mr trades about 47,812 units every 0 days since 2022. As of 28 October 2022 he still owns at least 69,293 units of Chembio Diagnostics stock.
You can see the complete history of Mr Angelico stock trades at the bottom of the page.
Paul J. Angelico is the VP of Global Operations at Chembio Diagnostics.
Paul's mailing address filed with the SEC is C/O CHEMBIO DIAGNOSTICS, INC., 3661 HORSEBLOCK ROAD, MEDFORD, NY, 11763.
Over the last 20 years, insiders at Chembio Diagnostics have traded over $909,824 worth of Chembio Diagnostics stock and bought 3,754,893 units worth $1,696,058 . The most active insiders traders include Credit Advisors, Llcpercept..., Lawrence A. Siebert és Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of $36,203. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth $109,552.
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
Chembio Diagnostics executives and other stock owners filed with the SEC include: